• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

作者信息

Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra M Giaj, Kerr K, Popat S, Reck M, Senan S, Simo G V, Vansteenkiste J, Peters S

机构信息

Oncology Department, University of Turin, AOU San Luigi-Orbassano, Orbassano, Italy.

Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Marseille, France.

出版信息

Ann Oncol. 2016 Sep;27(suppl 5):v1-v27. doi: 10.1093/annonc/mdw326.

DOI:10.1093/annonc/mdw326
PMID:27664245
Abstract
摘要

相似文献

1
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.转移性非小细胞肺癌：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2016 Sep;27(suppl 5):v1-v27. doi: 10.1093/annonc/mdw326.
2
Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.辅助化疗（CT）和放疗（RT）在未完全切除（R1）的早期非小细胞肺癌（NSCLC）中的应用：欧洲医学肿瘤学会（ESMO）青年肿瘤学家委员会进行的一项欧洲调查。
Lung Cancer. 2014 Jul;85(1):74-80. doi: 10.1016/j.lungcan.2014.03.010. Epub 2014 Mar 16.
3
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".对《转移性非小细胞肺癌：ESMO诊断、治疗及随访临床实践指南》的勘误
Ann Oncol. 2019 May;30(5):863-870. doi: 10.1093/annonc/mdy474. Epub 2019 Dec 4.
4
Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.非小细胞肺癌：欧洲肿瘤内科学会（ESMO）关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:68-70. doi: 10.1093/annonc/mdp132.
5
Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.小细胞肺癌：欧洲肿瘤内科学会关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:71-2. doi: 10.1093/annonc/mdp133.
6
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.胆管癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37. doi: 10.1093/annonc/mdw324.
7
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.食管癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2016 Sep;27(suppl 5):v50-v57. doi: 10.1093/annonc/mdw329.
8
How do lung cancer specialists follow their patients with stage III non-small cell lung cancer (NSCLC) after definitive treatment? A short report.肺癌专家如何对接受明确治疗后的 III 期非小细胞肺癌（NSCLC）患者进行随访？一份简短报告。
Eur J Cancer. 2012 Sep;48(14):2163-5. doi: 10.1016/j.ejca.2012.04.006. Epub 2012 May 26.
9
Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.美国医疗保险转移性鳞状非小细胞肺癌患者的真实世界治疗模式和费用。
Lung Cancer. 2015 Feb;87(2):176-85. doi: 10.1016/j.lungcan.2014.11.002. Epub 2014 Nov 8.
10
Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.局部复发或转移性乳腺癌：欧洲肿瘤内科学会关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:15-8. doi: 10.1093/annonc/mdp115.

引用本文的文献

1
Treatment Response and Survival in Thyroid Transcription Factor-1 Negative Non-squamous Non-small Cell Lung Cancer.甲状腺转录因子-1阴性非鳞状非小细胞肺癌的治疗反应与生存情况
Cancer Diagn Progn. 2025 Sep 1;5(5):583-590. doi: 10.21873/cdp.10472. eCollection 2025 Sep-Oct.
2
Real-World Outcomes of T790M Mutation Testing and Sequential Osimertinib in EGFR-Positive Advanced Non-small Cell Lung Cancer: A Revisited Strategy.T790M 突变检测及序贯使用奥希替尼治疗 EGFR 阳性晚期非小细胞肺癌的真实世界结局：一种重新审视的策略
Target Oncol. 2025 Sep 2. doi: 10.1007/s11523-025-01173-1.
3
Cost-effectiveness analysis of penpulimab plus carboplatin-paclitaxel as first-line treatment for metastatic squamous non-small-cell lung cancer in China.
在中国，派安普利单抗联合卡铂-紫杉醇作为转移性鳞状非小细胞肺癌一线治疗的成本效益分析。
Health Econ Rev. 2025 Jul 12;15(1):60. doi: 10.1186/s13561-025-00656-1.
4
Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.帕博利珠单抗单药治疗高程序性死亡配体1表达的晚期或转移性非小细胞肺癌的成本效益取决于长期存活者。
Clin Drug Investig. 2025 Jul 9. doi: 10.1007/s40261-025-01456-5.
5
Tumor-associated macrophages derived exosomal circPLK1 promotes resistance to EGFR inhibitor osimertinib in non-small cell lung cancer.肿瘤相关巨噬细胞衍生的外泌体环状PLK1促进非小细胞肺癌对表皮生长因子受体抑制剂奥希替尼的耐药性。
Discov Oncol. 2025 Jul 1;16(1):1196. doi: 10.1007/s12672-025-03025-w.
6
Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials.抗体药物偶联物用于肺癌治疗的疗效和安全性：对随机和非随机临床试验的系统评价
Pharmaceutics. 2025 May 3;17(5):608. doi: 10.3390/pharmaceutics17050608.
7
Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis.安罗替尼联合多西他赛用于铂类化疗后进展的晚期非小细胞肺癌的疗效：一项系统评价和Meta分析
Pharmaceuticals (Basel). 2025 Apr 29;18(5):652. doi: 10.3390/ph18050652.
8
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of + NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III -Mutated NSCLC Compared to Placebo (LAURA, NCT03521154).LAURA 完成了奥希替尼治疗 IB 期至 IV 期非小细胞肺癌（NSCLC）的拼图：与安慰剂相比，辅助奥希替尼显著改善了不可切除的 III 期 EGFR 突变型 NSCLC 的无进展生存期（PFS）和中枢神经系统进展（LAURA，NCT03521154）。
Lung Cancer (Auckl). 2025 Apr 25;16:51-55. doi: 10.2147/LCTT.S520833. eCollection 2025.
9
Serum and exosome WNT5A levels as biomarkers in non-small cell lung cancer.血清和外泌体WNT5A水平作为非小细胞肺癌的生物标志物
Respir Res. 2025 Apr 13;26(1):141. doi: 10.1186/s12931-025-03216-7.
10
Predicting a failure of postoperative thromboprophylaxis in non-small cell lung cancer: A stacking machine learning approach.预测非小细胞肺癌术后血栓预防失败：一种堆叠式机器学习方法。
PLoS One. 2025 Apr 1;20(4):e0320674. doi: 10.1371/journal.pone.0320674. eCollection 2025.